Prevalence of Ivermectin use to prevent COVID-19 during the pandemic in Mato Grosso: cross-sectional home-based study

Author:

Silva Nathalia Beatriz Lobo da1ORCID,Rocha Roseany Patrícia da Silva1ORCID,Andrade Amanda Cristina de Souza1ORCID,Terças-Trettel Ana Cláudia Pereira2ORCID,Muraro Ana Paula1ORCID

Affiliation:

1. Universidade Federal de Mato Grosso, Brazil

2. Universidade do Estado de Mato Grosso, Brazil; Universidade Federal de Mato Grosso, Brazil

Abstract

ABSTRACT Objective: To analyze the use of ivermectin as COVID-19 prevention method by the population of Mato Grosso in 2020. Methods: This is a home-based survey, carried out between September and October 2020, in 10 pole cities of the socioeconomic regions of State. The use of ivermectin was evaluated through the question: “Did you take ivermectin to prevent COVID-19?”. Sociodemographic variables (sex, age group, education, family income), current work situation, being benefitted by government financial programs, as well as symptoms, seroprevalence of antibodies against SARS-CoV-2, and previous diagnosis of COVID-19 were evaluated. Prevalence and their associations were estimated using the chi-square test. Results: 4.206 individuals were evaluated for prevalence of ivermectin use; 58.3% of the individuals responded positively, this rate being higher in the municipalities of the western region of the state (66.6%). There was no significant difference between sexes, but the prevalence was higher among people aged 50–59 years (69.7%), who were white (66.5%), with complete higher education or more (68.8%) and higher family income (≥3 minimum wages-64.2%). The use of this drug was even higher among participants who considered their knowledge of the disease good or very good (65.0%), who reported having symptoms of COVID-19 (75.3%), and who had been previously diagnosed with the disease (91.2%). Conclusion: There was a high prevalence of use of ivermectin as a method to prevent covid-19 by the population of Mato Grosso, indicating the need for strategies to inform the population about the risks of off-label use of drugs and to combat the advertising of drugs that are ineffective against COVID-19.

Publisher

FapUNIFESP (SciELO)

Subject

Epidemiology,Public Health, Environmental and Occupational Health,General Medicine

Reference24 articles.

1. Infodemics and infodemiology: a short history, a long future;Zielinski C;Rev Panam Salud Publica,2021

2. Infodemia: excesso de quantidade em detrimento da qualidade das informações sobre a COVID-19;Garcia LP;Epidemiol Serv Saúde,2020

3. Ivermectin for preventing and treating COVID-19;Popp M;Cochrane Database Syst Rev,2021

4. Automedicação e uso indiscriminado de medicamentos durante a pandemia da COVID-19;Melo JRR;Cad Saúde Pública,2021

5. Effect of ivermectin vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19 a randomized clinical trial;Naggie S;JAMA,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3